人体内O-(2-18F-氟代乙基)-L-酪氨酸辐射吸收剂量的估算

为评估人体内O-(2-^18F-氟代乙基)-L-酪氨酸(FET)吸收剂量，选择小鼠作为模型。由小鼠尾静脉注射FET后，在10、30、60、120和180min时处死动物，测定小鼠体内各脏器放射性分布，换算至标准人体内分布数据，按标准医学内照射吸收剂量(MIRD)计算法，估算人体内FET辐射吸收剂量。结果表明：人体骨内照射吸收剂量最高，其值为4．78pGy／Bq，脑和全身内照射吸收剂量最低，约为1．6pGy／Bq，其它脏器内照射吸收剂量为1．6～3．5pGy／Bq，有效剂量为9．0pSv／Bq。按一次静脉注射FET注射液370MBq估算，有效剂量为3．3mSv，其值处在常规核医学研究中可接受的有效剂量范围之内。

Human Dosimetric Estimation of O-(2-18F-fluoroethyl)-L-tyrosine Based on Mice Biodistribution Data

To estimate the human radiation absorbed doses of O-(2-~(18)F-fluoroethyl)-L-tyrosine (FET), mice are considered as model. FET is injected into mice through a tail vein. At 10, 30, 60, 120 and 180 min after injection, the mice are killed by cervical fracture and the biodistribution in mice are determined. Human dosimetric estimation is performed from the biodistribution of FET in mice and the standard Medical Internal Radiation Dose (MIRD) method using time - fractional radioactivity curves for humans. The bone in human is the organ receiving highest dose of 4.78 pGy/Bq, the brain and the whole body receive the lowest dose of 1.6 pGy/Bq, and other organs receive doses between 1.6 and 3.5 pGy/Bq. The effective dose is estimated to be 9.0 pSv/Bq. The data show that a 370 MBq injection of FET leads to an estimated effective dose of 3.3 mSv, which is in the range of routine nuclear medicine investigations. The potential radiation risks associated with this study are well within accepted limits.